Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
GlucoSet logo — Intensive care monitoring

GlucoSet

Intensive care monitoring

Founded 2011 Norway Norway 16 employees Total: $8.50M Biotechnology, Health Care +1

General Information

Company Name GlucoSet
Founded Year 2011
Location Norway Norway
Employees 16
Industries Biotechnology, Health Care, Medical Devices
Business Model B2B, B2B2C
Revenue Model Product Sales, Usage Based, Tiered Pricing
Social

BounceWatch is an independent company data service, not affiliated with GlucoSet. To contact GlucoSet, visit glucoset.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does GlucoSet compare?

A PDF of GlucoSet and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting GlucoSet soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About GlucoSet

GlucoSet, founded in 2011 and headquartered in Norway, is poised to revolutionize the Intensive Care Unit (ICU) environment with its cutting-edge biotechnology solutions. The company operates in the Biotechnology, Health Care, and Medical Devices industries, focusing on addressing critical health challenges in ICUs.

The company's mission, encapsulated by its slogan, "Intensive care monitoring," is to enhance patient outcomes by providing continuous and accurate monitoring of blood glucose levels. With elevated and unstable glucose levels being common and dangerous in ICU patients, GlucoSet's intravascular sensor technology promises to reduce complications, mortality rates, and healthcare costs through precise glucose control.

Recently, the company attracted investment from EIT Health through a Support Program investment dated 01 January 2025. This infusion of capital is expected to accelerate their technology's development and deployment, making GlucoSet an attractive prospect for investors in the med-tech space.

Business keywords: Intensive Care Unit, Glucose Monitoring, Intravascular Sensors, Continuous Monitoring, Blood Glucose Control, Patient Outcomes, Healthcare Cost Reduction, Patient Safety, Infection Prevention, Sensor Technology, Clinical Application, Critical Care Solutions

Services & Products

Continuous blood glucose monitoring devices
Minimally invasive sensor solutions
ICU cost reduction strategies
Glucose normalization technology

Target Customers

Hospitals Intensive Care Units Healthcare Providers Medical Professionals Healthcare Systems

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Support Program Undisclosed 1
EIT Health
01 Jan 2025
Grant €6.00M 3
Serpentine VC
Serpentine VC, EIC Fund +1
01 Jul 2023
Grant $2.50M 1
EIC Fund
01 Jun 2022
Support Program Undisclosed 1
EIT Health
01 Jan 2022
Spinout Undisclosed 1
Norwegian University of Science and Technology
01 Jan 2011

GlucoSet Alternatives & Competitors

View All Alternatives
GlucoSet vs
MELLIsim
MELLIsim France

Diabetes care for Type 2

1 employees
Health Care, Medical Devices
GlucoSet vs
OptiScan Biomedical Corporation
OptiScan Biomedical Corporation United States

Precision Glucose Monitoring for ICU and CCU Care

Series E
1 employees
Biotechnology, Health Care
GlucoSet vs
Vios Medical
Vios Medical United States

The Vios Monitoring System is a wireless, FDA-cleared medical device that enables continuous monitor...

Venture round
22 employees
Health Care, IT
Also compare with: GlucoSet vs Masimo Masimo View all alternatives

FAQ About GlucoSet

Intensive care monitoring
GlucoSet was founded in 2011.
GlucoSet is headquartered in Norway.
GlucoSet operates in Biotechnology, Health Care and Medical Devices. Its work centres on Intensive Care Unit, Glucose Monitoring, Intravascular Sensors and Continuous Monitoring. Its customers include Hospitals, Intensive Care Units and Healthcare Providers.
GlucoSet has a B2B and B2B2C business model. Its revenue comes from Product Sales, Usage Based and Tiered Pricing.
GlucoSet has approximately 16 employees.
GlucoSet has completed 5 funding rounds, raising a total of $8.50M.
GlucoSet offers: Continuous blood glucose monitoring devices, Minimally invasive sensor solutions, ICU cost reduction strategies, Glucose normalization technology.
Top alternatives and competitors to GlucoSet include MELLIsim, OptiScan Biomedical Corporation, Vios Medical, Serenno Medical, Masimo. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
GlucoSet and MELLIsim are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for GlucoSet, https://bouncewatch.com/company/glucoset, updated 6 August 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout